History of Zivolife

1933: Entrepreneurs notice a low incidence of arthritis and other autoimmune diseases in the villages surrounding an alpine lake in Germany and decide to collect the local water.

1945-1980: The water from the alpine lake is transported to the United States and cultivated. This water sample, considered a polyculture containing various aquatic species such as algae, fungi, and microorganisms, becomes the basis for a home remedy known as Lebenszeit, which translates to "lifetime" in English. Once the microorganisms are strained and removed, Lebenszeit is consumed as a drink.
1980-2003: Lebenszeit is commercialized and marketed as ProAlgaZyme. While cultivation methods are refined and standardized during this period, the product remains small-scale, and quality control proves challenging. ProAlgaZyme continues to be sold as a concentrated liquid, with the microorganisms from the polyculture removed.
2003-2016: Zivo Bioscience, Inc. (ZIVO) acquires the technology and embarks on scientific research to elucidate the product's specific health benefits and substantiate health claims through studies in both humans and animals. Research supports the benefits of ProAlgaZyme in cardiovascular health, autoimmune disorders, inflammation, weight loss, and disease recovery.

Weight Loss and Cardiovascular Benefits

ProAlgaZyme was a previous product whose key bioactive organism was Klebsormidium flaccidum var Zivo which later became Zivolife.

In a carefully conducted clinical trial adhering to FDA regulations and approved by an Institutional Review Board, individuals with a BMI of 25-40 participated in a weight loss study. 

They consumed one ounce of either ProAlgaZyme or placebo thrice daily on an empty stomach and followed a reduced carbohydrate diet and light exercise regimen. Results showed significant weight loss and improved glucose control in the ProAlgaZyme group compared to the placebo group. 

After six weeks of treatment, The ProAlgaZyme group showed statistically significant reductions in weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein, and fasting blood glucose levels and a statistically significant increase in HDL-cholesterol. No side effects were noted. Participants in the ProAlgaZyme group experienced an average weight loss of 106% (Cohort 1) and 37% (Cohort 2) more than those in the placebo group. Additionally, participants reported greater energy and reduced hunger while on ProAlgaZyme. Importantly, no significant adverse events were reported during the trial.

Oben, J., Enonchong, E., Kuate, D., Mbanya, D., Thomas, T.C., Hildreth, D.J., Ingolia, T.D., and Tempesta, M.S., 2007. The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health. Lipids in Health and Disease 6, 20. https://doi.org/10.1186/1476-511X-6-20

Thomas, T. and Tempesta, T. 2014. Composition and use of phyto-percolate for treatment of disease. United States. US8791060B2. https://patents.google.com/patent/US8791060B2/en?oq=US20110081319A1 

2016-2023: Through extensive research, Zivo Bioscience identifies Klebsormidium as the key bioactive organism and subsequently isolates, registers, and develops cultivation methods for Klebsormidium flaccidum var ZL01, also known as Zivolife. ZIVO continues to expand its understanding of the culture and health benefits through scientific studies and patents utilizing biomass from Klebsormidium flaccidum var ZL01.


Anti-inflammatory study

Zivolife, derived from the green alga Klebsormidium flaccidum var. Zivo 01, is rich in proteins, polyphenols, and bioactive small-molecule compounds. Various anti-inflammatory compounds within Zivolife have been identified through advanced scientific methods, including hydroxylated fatty acids, chlorophyll-derived pheophorbides, carotenoids, and glycoglycerolipids. One particularly potent compound, pheophorbide a, has shown remarkable anti-inflammatory activity by inhibiting nitric oxide production and nuclear factor kappaB activation in different cellular models. 

This breakthrough research highlights the efficiency of a novel approach that combines chromatographic fractionation, anti-inflammatory activity testing, ultrahigh-performance liquid chromatography-mass spectrometry profiling, and chemometric analysis. By rapidly identifying multiple chemical classes of bioactive compounds from Zivolife, this approach paves the way for harnessing the full potential of this natural product for promoting overall health and combating inflammation. 

In summary, Zivolife is a promising source of anti-inflammatory compounds, offering a holistic solution for those seeking natural ways to support their well-being and combat inflammation.

Qiu, S., Khan, S.I., Wang, M., Zhao, J., Ren, S., Khan, I.A., Steffek, A., Pfund, W.P., and Li, X.-C., 2020. Chemometrics-assisted identification of anti-inflammatory compounds from the Green Alga Klebsormidium flaccidum var. ZIVO. Molecules 25(5):1048. https://doi.org/10.3390/molecules25051048


In November 2023 ZIVO was awarded US and international patents Dahl and Steffek 2023a (US11806375B2). Patent covers food, feed and nutritional supplements comprising an algal biomass from Klebsormidium derived thereof. Klebsormidium maintains general health in humans and non-human animals and promotes a healthy immune system.

Methods for promoting or supporting a healthy immune system, reducing or preventing recurrence of a disease, preventing, reducing or delaying the onset or recurrence of an effect of stress in a human or non-human animal comprises administering to the animal in need thereof and/or promoting general health in an animal, human or non-human, by administering to the animal in need thereof, a prophylactically effective amount of a Klebsormidium algal biomass.

Dahl, A. A. and Steffek, A. E. 2023a. Nutritional support for animals via administration of an algal derived supplement. United States. US11806375B2. https://patents.google.com/patent/US11806375B2/en?oq=US11806375B2

Dahl, A. A. and Steffek, A. E. 2023b. Anti-inflammatory and immunomodulatory compositions comprising Klebsormidium and uses thereof. European Patent Office. EP3258948B1. https://patents.google.com/patent/EP3258948B1/en?oq=EP3258948B1